Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual
ConditionOpioid Use Disorder
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNew York State Psychiatric Institute
About this trial
This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).
Eligibility criteria
Qualifiers
meet DSM-5 criteria for OUD
Voluntarily seeking buprenorphine treatment for OUD
Able to provide informed consent and comply with study procedures
Disqualifiers
Meeting DSM-5 criteria for substance use disorder other than opioid as the primary diagnosis that would compromise safety of participation in the trial as determined by the study physician, such as an alcohol or sedative hypnotic use disorder that requires detoxification
Having a comorbid psychiatric diagnosis that might interfere with participation or make participation hazardous, such as a psychotic disorder including schizophrenia or schizoaffective disorder
Concurrent methadone, buprenorphine, or vivitrol maintenance treatment
Known history of allergy, intolerance, or hypersensitivity to candidate medication (buprenorphine)
Trial design
Treatments tested in this trial
- Buprenorphine SL
- Telehealth
- In-person treatment as usual
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
New York State Psychiatric Institute
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov